RESUMO
In the cut-throat industry of academic publishing, some journals barely survive a decade, let alone a century, but in October 2023, Journal of Experimental Biology is celebrating 100â years at the forefront of comparative physiology, neuroethology and biomechanics. In this Commentary article and the accompanying poster, I explore the journal's history from its inception, through the guidance of nine Editors-in-Chief, to achieving its aims of championing the comparative approach, disseminating and promoting high-quality research and supporting our community of researchers. I discuss technological developments in publishing and classic articles that have cemented the journal in its position at the forefront of comparative physiology.
Assuntos
Pescoço , Editoração , Fenômenos Biomecânicos , BiologiaRESUMO
With a century of literature behind Journal of Experimental Biology (JEB) in 2023, I look at some of the extraordinary papers contained within its archive. From publishing Nobel Prize-inspiring discoveries to founding fields and solving long-standing mysteries, the journal has been at the hub of experimental biology for 10 decades, leading the way and shining a light on the physiology of many remarkable animal species. In this Perspective, I highlight some of the key players in the field, summarise their seminal works and consider their long-term impact as JEB embarks on its next 100â years.
Assuntos
Prêmio Nobel , Editoração , AnimaisRESUMO
Multiple-herbicide resistance (MHR) in black-grass (Alopecurus myosuroides) and annual rye-grass (Lolium rigidum) is a global problem leading to a loss of chemical weed control in cereal crops. Although poorly understood, in common with multiple-drug resistance (MDR) in tumors, MHR is associated with an enhanced ability to detoxify xenobiotics. In humans, MDR is linked to the overexpression of a pi class glutathione transferase (GSTP1), which has both detoxification and signaling functions in promoting drug resistance. In both annual rye-grass and black-grass, MHR was also associated with the increased expression of an evolutionarily distinct plant phi (F) GSTF1 that had a restricted ability to detoxify herbicides. When the black-grass A. myosuroides (Am) AmGSTF1 was expressed in Arabidopsis thaliana, the transgenic plants acquired resistance to multiple herbicides and showed similar changes in their secondary, xenobiotic, and antioxidant metabolism to those determined in MHR weeds. Transcriptome array experiments showed that these changes in biochemistry were not due to changes in gene expression. Rather, AmGSTF1 exerted a direct regulatory control on metabolism that led to an accumulation of protective flavonoids. Further evidence for a key role for this protein in MHR was obtained by showing that the GSTP1- and MDR-inhibiting pharmacophore 4-chloro-7-nitro-benzoxadiazole was also active toward AmGSTF1 and helped restore herbicide control in MHR black-grass. These studies demonstrate a central role for specific GSTFs in MHR in weeds that has parallels with similar roles for unrelated GSTs in MDR in humans and shows their potential as targets for chemical intervention in resistant weed management.
Assuntos
Glutationa Transferase/fisiologia , Resistência a Herbicidas/genética , Herbicidas/farmacologia , Plantas Daninhas/enzimologia , Poaceae/enzimologia , Arabidopsis/genética , Regulação da Expressão Gênica de Plantas , Genes de Plantas , Glutationa Transferase/genética , Análise de Sequência com Séries de Oligonucleotídeos , Fenótipo , Plantas Daninhas/genética , Plantas Geneticamente Modificadas , Poaceae/genética , TransgenesAssuntos
Distinções e Prêmios , Biologia , Invertebrados/fisiologia , Vertebrados/fisiologia , AnimaisRESUMO
A man in his 30s was referred to neurology with right-sided paraesthesia, tremors, chest pain and lower urinary tract and erectile dysfunction. He had a medical history of left acetabular dysplasia, and subjective memory impairment, the latter being in the context of depression and chronic pain with opioid use. There was no notable family history. On examination, he had a spastic paraparesis. Imaging revealed atrophy of the thoracic spine. Lumbar puncture demonstrated a raised protein but other constituents were normal, including no presence of oligoclonal bands. Genetic testing revealed a novel heterozygous likely pathogenic SPAST variant c. 1643A>T p.(Asp548Val), confirming the diagnosis of hereditary spastic paraparesis. Symptomatic treatment with physiotherapy and antispasmodic therapy was initiated. This is the first study reporting a patient with this SPAST variant. Ensembl variant effect predictor was used, with the application of computational variant prediction tools providing support that the variant we have identified is likely deleterious and damaging. Our variant CADD score was high, indicating that our identified variant was a highly deleterious substitution.
Assuntos
Paraparesia Espástica , Paraplegia Espástica Hereditária , Humanos , Masculino , Testes Genéticos , Mutação , Paraparesia Espástica/genética , Linhagem , Proteínas/genética , Paraplegia Espástica Hereditária/genética , Espastina/genética , AdultoRESUMO
BACKGROUND: Injection drug use (IDU) can increase mortality and morbidity. Therefore, identifying IDU early and initiating harm reduction interventions can benefit individuals at risk. However, extracting IDU behaviors from patients' electronic health records (EHR) is difficult because there is no other structured data available, such as International Classification of Disease (ICD) codes, and IDU is most often documented in unstructured free-text clinical notes. Although natural language processing can efficiently extract this information from unstructured data, there are no validated tools. METHODS: To address this gap in clinical information, we design a question-answering (QA) framework to extract information on IDU from clinical notes for use in clinical operations. Our framework involves two main steps: (1) generating a gold-standard QA dataset and (2) developing and testing the QA model. We use 2323 clinical notes of 1145 patients curated from the US Department of Veterans Affairs (VA) Corporate Data Warehouse to construct the gold-standard dataset for developing and evaluating the QA model. We also demonstrate the QA model's ability to extract IDU-related information from temporally out-of-distribution data. RESULTS: Here, we show that for a strict match between gold-standard and predicted answers, the QA model achieves a 51.65% F1 score. For a relaxed match between the gold-standard and predicted answers, the QA model obtains a 78.03% F1 score, along with 85.38% Precision and 79.02% Recall scores. Moreover, the QA model demonstrates consistent performance when subjected to temporally out-of-distribution data. CONCLUSIONS: Our study introduces a QA framework designed to extract IDU information from clinical notes, aiming to enhance the accurate and efficient detection of people who inject drugs, extract relevant information, and ultimately facilitate informed patient care.
There are many health risks associated with injection drug use (IDU). Identifying people who inject drugs early can reduce the likelihood of these issues arising. However, extracting information about any possible IDU from a person's electronic health records can be difficult because the information is often in text-based general clinical notes rather than provided in a particular section of the record or as numerical data. Manually extracting information from these notes is time-consuming and inefficient. We used a computational method to train computer software to be able to extract IDU details. Potentially, this approach could be used by healthcare providers to more efficiently and accurately identify people who inject drugs, and therefore provide better advice and medical care.